4530.T
Hisamitsu Pharmaceutical Co., Inc. [4530.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4530.T Stock Summary
Top 10 Correlated ETFs
4530.T
Top 10 Correlated Stocks
4530.T
In the News
4530.T Financial details
Company Rating
Buy
Market Cap
296.08B
Income
13.97B
Revenue
141.71B
Book val./share
-
Cash/share
-
Dividend
42.75
Dividend %
0.95%
Employees
2.77K
Optionable
No
Shortable
Yes
Earnings
11 Jul 2024
P/E
25.66
Forward P/E
-
PEG
11.23
P/S
2.57
P/B
1.28
P/C
-
P/FCF
-
Quick Ratio
3.38
Current Ratio
3.97
Debt / Equity
0.01
LT Debt / Equity
0
-
-
EPS (TTM)
181.82
EPS next Y
-
EPS next Q
-
EPS this Y
22.72%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.41%
Revenue last 5Y
0.1%
Revenue Q/Q
8.45%
EPS Q/Q
-48.54%
-
-
-
-
SMA20
-1.1%
SMA50
-7.99%
SMA100
-15.92%
Inst Own
-
Inst Trans
-
ROA
4%
ROE
5%
ROC
0.05%
Gross Margin
57%
Oper. Margin
11%
Profit Margin
10%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3541.0-5497.0
52W High
-32%
52W Low
+5.56%
RSI
33
Rel Volume
1.19
Avg Volume
164.67K
Volume
196.3K
Perf Week
-5.61%
Perf Month
-1.66%
Perf Quarter
-22.22%
Perf Half Y
-23.67%
-
-
-
-
Beta
0.404
-
-
Volatility
87.04%, 83.76%
Prev Close
0.35%
Price
3738
Change
-1.63%
4530.T Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2024-02-29
| Metric | History | 2020-02-29 | 2021-02-28 | 2022-02-28 | 2023-02-28 | 2024-02-29 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.72K | 1.4K | 1.48K | 1.62K | 1.84K | |
| Net income per share | 227.58 | 113.21 | 118.92 | 148 | 181.62 | |
| Operating cash flow per share | 333.5 | 64.73 | 236.4 | 160.41 | 236.46 | |
| Free cash flow per share | 288.14 | 23.27 | 184.77 | 60.74 | 66.98 | |
| Cash per share | 1.73K | 1.66K | 1.75K | 1.73K | 1.63K | |
| Book value per share | 3.03K | 3.09K | 3.12K | 3.23K | 3.44K | |
| Tangible book value per share | 3.03K | 3.09K | 3.12K | 3.25K | 3.45K | |
| Share holders equity per share | 3.03K | 3.09K | 3.12K | 3.23K | 3.44K | |
| Interest debt per share | 21.84 | 19.73 | 30.54 | 29.12 | 19.7 | |
| Market cap | 397.16B | 548.25B | 297.24B | 303.08B | 297.98B | |
| Enterprise value | 291.89B | 435.6B | 170.41B | 183.22B | 187.62B | |
| P/E ratio | 21.25 | 59.27 | 30.78 | 25.81 | 21.33 | |
| Price to sales ratio | 2.82 | 4.79 | 2.47 | 2.36 | 2.1 | |
| POCF ratio | 14.5 | 103.66 | 15.48 | 23.81 | 16.38 | |
| PFCF ratio | 16.78 | 288.4 | 19.81 | 62.89 | 57.84 | |
| P/B Ratio | 1.59 | 2.17 | 1.17 | 1.18 | 1.12 | |
| PTB ratio | 1.59 | 2.17 | 1.17 | 1.18 | 1.12 | |
| EV to sales | 2.07 | 3.8 | 1.42 | 1.43 | 1.32 | |
| Enterprise value over EBITDA | 9.76 | 26.95 | 10.04 | 8.72 | 10.23 | |
| EV to operating cash flow | 10.65 | 82.36 | 8.88 | 14.4 | 10.32 | |
| EV to free cash flow | 12.33 | 229.14 | 11.36 | 38.02 | 36.42 | |
| Earnings yield | 0.05 | 0.02 | 0.03 | 0.04 | 0.05 | |
| Free cash flow yield | 0.06 | 0 | 0.05 | 0.02 | 0.02 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Net debt to EBITDA | -3.52 | -6.97 | -7.47 | -5.7 | -6.02 | |
| Current ratio | 5.1 | 6.59 | 6.22 | 4.68 | 4.22 | |
| Interest coverage | 1.2K | 1.07K | 466.85 | 773.27 | 731.56 | |
| Income quality | 1.05 | 0.43 | 1.48 | 0.79 | 1.3 | |
| Dividend Yield | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
| Payout ratio | 0.37 | 0.74 | 0.71 | 0.57 | 0.47 | |
| Sales general and administrative to revenue | 0.16 | 0.18 | 0.17 | 0.18 | 0 | |
| Research and developement to revenue | 0.07 | 0.09 | 0.09 | 0.08 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.14 | -0.64 | -0.22 | -0.62 | -0.72 | |
| Capex to revenue | -0.03 | -0.03 | -0.03 | -0.06 | -0.09 | |
| Capex to depreciation | -0.88 | -0.83 | -0.97 | -1.6 | -2.52 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.94K | 2.8K | 2.89K | 3.28K | 3.75K | |
| ROIC | 0.07 | 0.03 | 0.03 | 0.03 | 0.04 | |
| Return on tangible assets | 0.06 | 0.03 | 0.03 | 0.04 | 0.04 | |
| Graham Net | 1.58K | 1.58K | 1.62K | 1.52K | 1.38K | |
| Working capital | 168.2B | 168B | 168.02B | 156.6B | 148.08B | |
| Tangible asset value | 249.27B | 252.63B | 253.56B | 257.46B | 265.64B | |
| Net current asset value | 152.59B | 152.01B | 152.2B | 143.66B | 132.33B | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 45.67B | 44.39B | 39.03B | 39.26B | 41.5B | |
| Average payables | 9.39B | 9.08B | 7.6B | 7.94B | 12.31B | |
| Average inventory | 15.61B | 17.01B | 17.49B | 17.67B | 20.05B | |
| Days sales outstanding | 127.45 | 126.05 | 116.93 | 113.81 | 110.71 | |
| Days payables outstanding | 71.7 | 61.77 | 54.85 | 54.79 | 94.62 | |
| Days of inventory on hand | 105.68 | 149.49 | 119.51 | 124.15 | 123.2 | |
| Receivables turnover | 2.86 | 2.9 | 3.12 | 3.21 | 3.3 | |
| Payables turnover | 5.09 | 5.91 | 6.65 | 6.66 | 3.86 | |
| Inventory turnover | 3.45 | 2.44 | 3.05 | 2.94 | 2.96 | |
| ROE | 0.07 | 0.04 | 0.04 | 0.05 | 0.05 | |
| Capex per share | -45.36 | -41.47 | -51.63 | -99.67 | -169.48 |
Quarterly Fundamentals Overview
Last date of statement is 2024-02-29 for Q4
| Metric | History | 2023-02-28 | 2023-05-31 | 2023-08-31 | 2023-11-30 | 2024-02-29 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 466.12 | 412.84 | 449.19 | 471.03 | 0 | |
| Net income per share | 28.39 | 52.08 | 56.25 | 48.52 | 0 | |
| Operating cash flow per share | 41.05 | 29.56 | 34.1 | 30.67 | 0 | |
| Free cash flow per share | 41.05 | 29.56 | 34.1 | 30.67 | 0 | |
| Cash per share | 1.75K | 1.76K | 1.82K | 1.63K | 0 | |
| Book value per share | 3.28K | 3.34K | 3.51K | 3.54K | 0 | |
| Tangible book value per share | 3.29K | 3.35K | 3.53K | 3.49K | 0 | |
| Share holders equity per share | 3.28K | 3.34K | 3.51K | 3.54K | 0 | |
| Interest debt per share | 29.39 | 15.46 | 15.32 | 15.39 | 0 | |
| Market cap | 298.71B | 279.1B | 383.76B | 351.47B | 0 | |
| Enterprise value | 178.85B | 158B | 257.9B | 241.5B | -110.36B | |
| P/E ratio | 33.64 | 17.23 | 21.96 | 23.79 | 0 | |
| Price to sales ratio | 8.2 | 8.7 | 11 | 9.8 | 0 | |
| POCF ratio | 93.06 | 121.45 | 144.93 | 150.59 | 0 | |
| PFCF ratio | 93.06 | 121.45 | 144.93 | 150.59 | 0 | |
| P/B Ratio | 1.17 | 1.08 | 1.41 | 1.31 | 0 | |
| PTB ratio | 1.17 | 1.08 | 1.41 | 1.31 | 0 | |
| EV to sales | 4.91 | 4.92 | 7.39 | 6.74 | -2.84 | |
| Enterprise value over EBITDA | 58.64 | 27.66 | 43.11 | 48.05 | -46.92 | |
| EV to operating cash flow | 55.72 | 68.76 | 97.4 | 103.47 | 0 | |
| EV to free cash flow | 55.72 | 68.76 | 97.4 | 103.47 | 0 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Free cash flow yield | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Debt to equity | 0.01 | 0 | 0 | 0 | 0.01 | |
| Debt to assets | 0.01 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -39.3 | -21.2 | -21.04 | -21.88 | -46.92 | |
| Current ratio | 4.68 | 4.48 | 3.97 | 3.98 | 4.22 | |
| Interest coverage | 1.03K | 0 | 576.43 | 774.8 | 149.67 | |
| Income quality | 1.45 | 0.57 | 0.61 | 0.63 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | -0.38 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.07 | 0.06 | 0.06 | 0.05 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0.02 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.45K | 1.98K | 2.11K | 1.96K | 0 | |
| ROIC | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Graham Net | 1.55K | 1.51K | 1.47K | 1.35K | 0 | |
| Working capital | 156.6B | 156.38B | 160.72B | 149.84B | 148.08B | |
| Tangible asset value | 257.46B | 260.75B | 274.18B | 265.93B | 265.64B | |
| Net current asset value | 143.66B | 142.82B | 145.71B | 136.76B | 132.33B | |
| Invested capital | 0.01 | 0 | 0 | 0 | 0.01 | |
| Average receivables | 38.89B | 39.4B | 40.38B | 42.19B | 42.7B | |
| Average payables | 9.34B | 7.86B | 8.64B | 9.99B | 13.16B | |
| Average inventory | 19.61B | 19.49B | 20.3B | 21.08B | 21.39B | |
| Days sales outstanding | 98.8 | 108.78 | 108.28 | 106.47 | 99.5 | |
| Days payables outstanding | 45.47 | 49.57 | 59.72 | 56.91 | 79.08 | |
| Days of inventory on hand | 103.02 | 134.87 | 123.68 | 122.32 | 102.97 | |
| Receivables turnover | 0.91 | 0.83 | 0.83 | 0.85 | 0.9 | |
| Payables turnover | 1.98 | 1.82 | 1.51 | 1.58 | 1.14 | |
| Inventory turnover | 0.87 | 0.67 | 0.73 | 0.74 | 0.87 | |
| ROE | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
4530.T Frequently Asked Questions
What is Hisamitsu Pharmaceutical Co., Inc. stock symbol ?
Hisamitsu Pharmaceutical Co., Inc. is a JP stock and trading under the symbol 4530.T
What is Hisamitsu Pharmaceutical Co., Inc. stock quote today ?
Hisamitsu Pharmaceutical Co., Inc. stock price is $3738 today.
Is Hisamitsu Pharmaceutical Co., Inc. stock public?
Yes, Hisamitsu Pharmaceutical Co., Inc. is a publicly traded company.
Company Profile
- Volume Average 164.67K
- Market Capitalization 296.08B
- Employee 2.77K
- CEO Mr. Kazuhide Nakatomi
- Headquarters Tosu,JP
- IPO Date 2001-01-01
-
Website
https://www.hisamitsu.co.jp 
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals, quasi-drugs, and medical devices in Japan. The company provides external pain relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; and BUTENALOCK, a remedy for athlete's foot, as well as ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, transdermal analgesic anti-inflammatory drug; patches for female hormone, asthma treatment, and treatment for overactive bladders. In addition, the company manufactures and sells drugs under MOHRUS TAPE, MOHRUS PAP XR, FENTOS Tapes, NEOXY Tapes, Abstral, ALLESAGA Tapes, HARUROPI Tapes, and MENOAID Combipatch. Further, it provides HFT-290, a transdermal patch for cancer pain. The company sells its products in the United States and Asia. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan.
